Drug profile · INN
danazol
DANOCRINE
danazol (DANOCRINE) is a progesterone receptor agonist. Associated with Beam Therapeutics. Route of administration: oral. Current US regulatory status: approved.
Drug details — danazol
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 10
- Programs
- 3
- Data quality
- 0.89
Quick answer
danazol (DANOCRINE) is a progesterone receptor agonist. Associated with Beam Therapeutics. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Progesterone receptor agonist
Primary target: Androgen receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12296053
Nanomaterials comprising triols
granted -
US 12268753
Nanomaterials comprising a biodegradable feature
granted -
US 12059477
Nanomaterials
granted -
US 12016908
Compositions and methods for treating hemoglobinopathies
granted -
US 11752202
Compositions and methods for treating hemoglobinopathies
granted -
US 11594345
Method for producing Ac-225 from Ra-226
granted -
US 11344609
Compositions and methods for treating hemoglobinopathies
granted -
US 11142760
Compositions and methods for treating hemoglobinopathies
granted -
US 10919019
Apparatus for the synthesis of radiopharmaceutical products
granted -
US 8287819
Device for synthesis of radiopharmaceutical products
granted
Frequently asked questions
What is danazol?
danazol (DANOCRINE) is a progesterone receptor agonist. Associated with Beam Therapeutics. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for danazol?
DANOCRINE is a marketed brand name for danazol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of danazol?
danazol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.